Developments in administration of growth hormone treatment: Focus on norditropin® flexpro®

Kevin C J Yuen, Rakesh Amin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently efficacy outcomes. To enhance potential treatment adherence, improved ease of use of growth hormone delivery devices and long-acting growth hormone formulations are now being developed. Flexpro®, approved by the US Food and Drug Administration in March 2010, is the most recent pen device developed by Novo Nordisk A/S to deliver Norditropin®. It is a multidose, premixed, preloaded, disposable pen device that requires relatively less force to inject and does not require refrigeration after initial use. Dose adjustments can be optimized by small dose increments of the pen delivery device at 0.025 mg, 0.05 mg and 0.1 mg. In addition, for patients with needle anxiety, NovoFine® needles, some of the shortest and thinnest available, and Autocover®, which hides the needle during injections, can be used with the Flexpro pen device. This article reviews the Norditropin Flexpro pen device in the context of other growth hormone delivery devices, sustained-release growth hormone formulations in development, and future prospects.

Original languageEnglish (US)
Pages (from-to)117-124
Number of pages8
JournalPatient Preference and Adherence
Volume5
DOIs
StatePublished - 2011

Fingerprint

Human Growth Hormone
Growth Hormone
Equipment and Supplies
Needles
Therapeutics
Social Adjustment
Refrigeration
United States Food and Drug Administration
Subcutaneous Injections
Treatment Failure
Anxiety
Injections
anxiety
Growth

Keywords

  • Adherence
  • Administration
  • Device
  • Growth hormone
  • Pen
  • Treatment

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Developments in administration of growth hormone treatment : Focus on norditropin® flexpro®. / Yuen, Kevin C J; Amin, Rakesh.

In: Patient Preference and Adherence, Vol. 5, 2011, p. 117-124.

Research output: Contribution to journalArticle

@article{fd0cae3abf014d2bb72aad6f34c19e40,
title = "Developments in administration of growth hormone treatment: Focus on norditropin{\circledR} flexpro{\circledR}",
abstract = "Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently efficacy outcomes. To enhance potential treatment adherence, improved ease of use of growth hormone delivery devices and long-acting growth hormone formulations are now being developed. Flexpro{\circledR}, approved by the US Food and Drug Administration in March 2010, is the most recent pen device developed by Novo Nordisk A/S to deliver Norditropin{\circledR}. It is a multidose, premixed, preloaded, disposable pen device that requires relatively less force to inject and does not require refrigeration after initial use. Dose adjustments can be optimized by small dose increments of the pen delivery device at 0.025 mg, 0.05 mg and 0.1 mg. In addition, for patients with needle anxiety, NovoFine{\circledR} needles, some of the shortest and thinnest available, and Autocover{\circledR}, which hides the needle during injections, can be used with the Flexpro pen device. This article reviews the Norditropin Flexpro pen device in the context of other growth hormone delivery devices, sustained-release growth hormone formulations in development, and future prospects.",
keywords = "Adherence, Administration, Device, Growth hormone, Pen, Treatment",
author = "Yuen, {Kevin C J} and Rakesh Amin",
year = "2011",
doi = "10.2147/PPA.S10985",
language = "English (US)",
volume = "5",
pages = "117--124",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Developments in administration of growth hormone treatment

T2 - Focus on norditropin® flexpro®

AU - Yuen, Kevin C J

AU - Amin, Rakesh

PY - 2011

Y1 - 2011

N2 - Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently efficacy outcomes. To enhance potential treatment adherence, improved ease of use of growth hormone delivery devices and long-acting growth hormone formulations are now being developed. Flexpro®, approved by the US Food and Drug Administration in March 2010, is the most recent pen device developed by Novo Nordisk A/S to deliver Norditropin®. It is a multidose, premixed, preloaded, disposable pen device that requires relatively less force to inject and does not require refrigeration after initial use. Dose adjustments can be optimized by small dose increments of the pen delivery device at 0.025 mg, 0.05 mg and 0.1 mg. In addition, for patients with needle anxiety, NovoFine® needles, some of the shortest and thinnest available, and Autocover®, which hides the needle during injections, can be used with the Flexpro pen device. This article reviews the Norditropin Flexpro pen device in the context of other growth hormone delivery devices, sustained-release growth hormone formulations in development, and future prospects.

AB - Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently efficacy outcomes. To enhance potential treatment adherence, improved ease of use of growth hormone delivery devices and long-acting growth hormone formulations are now being developed. Flexpro®, approved by the US Food and Drug Administration in March 2010, is the most recent pen device developed by Novo Nordisk A/S to deliver Norditropin®. It is a multidose, premixed, preloaded, disposable pen device that requires relatively less force to inject and does not require refrigeration after initial use. Dose adjustments can be optimized by small dose increments of the pen delivery device at 0.025 mg, 0.05 mg and 0.1 mg. In addition, for patients with needle anxiety, NovoFine® needles, some of the shortest and thinnest available, and Autocover®, which hides the needle during injections, can be used with the Flexpro pen device. This article reviews the Norditropin Flexpro pen device in the context of other growth hormone delivery devices, sustained-release growth hormone formulations in development, and future prospects.

KW - Adherence

KW - Administration

KW - Device

KW - Growth hormone

KW - Pen

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=80052775625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052775625&partnerID=8YFLogxK

U2 - 10.2147/PPA.S10985

DO - 10.2147/PPA.S10985

M3 - Article

C2 - 21448295

AN - SCOPUS:80052775625

VL - 5

SP - 117

EP - 124

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -